CD274 and non-small cell lung carcinoma: For advanced NSCLC without actionable genomic alterations (AGAs), first-line immunotherapy monotherapy in PD-L1 high NSCLC or combination with platinum-based chemotherapy, regardless of PD-L1 status, has become the standard of care (SOC).